Condition Directory

Ovarian Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Ovarian Cancer. Browse Ovarian Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 17, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

740

Shown on this page

Current sort

How Ovarian Cancer studies are organized in the registry

Ovarian cancer records are commonly registered as a group — “ovarian, fallopian tube, or primary peritoneal cancer” — so the broader phrasing is normal and not a labeling error. Platinum-sensitivity language (“platinum-resistant,” “platinum-sensitive”) and BRCA status frequently define the study population in titles.

Terms that often appear in related listings

platinum-resistant fallopian tube BRCA PARP

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 625–636 of 740 matching trials for Ovarian Cancer.

Live ClinicalTrials.gov results.

Active filters: "fallopian tube" Clear condition filters

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions: Farletuzumab, Chemo Plus Far; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 18
States / cities: San Diego, California • Indianapolis, Indiana • Covington, Louisiana + 15 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Panitumumab; Biological
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Leydig Cell Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Pseudomyxoma Peritonei, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Recurrent Uterine Sarcoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer
Interventions: stereotactic body radiation therapy, carboplatin, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacogenomic studies; Radiation · Drug · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Bladder Cancer
Interventions: belinostat, Paclitaxel, Carboplatin; Drug
Lead sponsor: Valerio Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 7
States / cities: Newport Beach, California • Orlando, Florida • Covington, Louisiana + 4 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Arm A: Vitamin D3 Group, Placebo; Dietary Supplement
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Chicago, Illinois • Evanston, Illinois

Conditions: Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Interventions: Not listed
Lead sponsor: OvaGene Oncology, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: Placebo, Gemcitabine, Pertuzumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 41
States / cities: Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 32 more

Conditions: Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Interventions: SJG-136, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 6
States / cities: Hartford, Connecticut • Tampa, Florida • New Brunswick, New Jersey + 2 more

Conditions: Ovarian Cancer, Endometrial Cancer
Interventions: everolimus and letrozole; Drug
Lead sponsor: Sinai Hospital of Baltimore; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Topotecan, Bevacizumab; Drug
Lead sponsor: Benaroya Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Undifferentiated Ovarian Carcinoma
Interventions: Carboplatin, Paclitaxel Poliglumex, Pharmacological Study; Drug · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer
Interventions: SS1(dsFv)-PE38 immunotoxin; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

About this Ovarian Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Ovarian Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Ovarian Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Ovarian Cancer clinical trials

How Ovarian Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

Panitumumab and Gemcitabine in Relapsed Ovarian Cancer

Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer

DNA Single Nucleotide Polymorphisms as Predictors of Toxicity

A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin

Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer

Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers

Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

Immunotoxin Therapy in Treating Patients With Advanced Cancer

About this Ovarian Cancer clinical trials directory page